Recent Updates
Recently added Catalysts
PRAX

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

Key Takeaway: Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
Price reaction · baseline $278.93 (2026-06-03 close) · hit after-hours · clean, no other PRAX news in the window
day 0 close
-5.1%
day 1
-8.9%
day 3 · peak
-10.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+61%
120-day peak, hindsight
Typical move
23.7%
average across 12 past catalysts
Cash runway
~53 mo
Minimal dilution risk
Lead asset
vormatrogine
Phase 3 · Epilepsy, Tonic-Clonic

Full Press Release Details

BOSTON, June 04, 2026 (GLOBE NEWSWIRE) --Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will be presenting a corporate overview at the Goldman Sachs 47thAnnual Global Healthcare Conference 2026 taking place in Miami, FL at the Loews Miami Beach Hotel on Monday, June 8, 2026 at 8:00am ET.
A live webcast of the event will be available through thislink. A replay of the event will also be available on Praxis’ “Events and Presentations” website after each event for approximately 180 days.
About PraxisPraxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visitwww.praxismedicines.comand follow us onFacebook,LinkedIn andX/Twitter.
Last updated: Jun 4, 2026